Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard
single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free
survival (PFS) in patients with chemotherapy refractory triple negative (ER/PR/HER2-negative)
LHRH-R positive metastatic breast cancer.